Hence, pharmaceutical companies have developed different GLP-1R agonists (GLP-1RAs) to target obesity and T2DM, which comprised multibillion-dollar businesses. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.